+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Psoriasis Induced by Anti-Tumor Necrosis Factor Alpha Agents: A Comprehensive Review of the Literature



Psoriasis Induced by Anti-Tumor Necrosis Factor Alpha Agents: A Comprehensive Review of the Literature



Acta Dermatovenerologica Croatica 24(3): 169-174



Tumor necrosis factor alpha (TNF-α) inhibitors revolutionized the management of patients affected by autoimmune diseases such as inflammatory bowel diseases, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. The biologic agents targeted to block TNF-α such as infliximab, adalimumab, certulizumab pegol, etanercept, and golimumab, have a good safety profile; however, with increasing, broader, and prolonged use, patients could be exposed to an increased risk of adverse reactions including a wide spectrum of dermatological conditions of different etiology and morphology. Among these, of particular interest is the development of skin immune-mediated diseases that seem to be the consequence of the paradoxical inflammation induced by anti-TNF-α therapy. The majority of these lesions are identified as psoriasiform with three main morphologies and different frequency: pustular psoriasis, signs of psoriasis, and guttate; although erythrodermic or inverted psoriasis, among others, may be observed with less frequency. The increased incidence of these dermatological immune-mediated lesions highlight the importance of the skin as a main target of the side effect of anti-TNF-α agents, while the immunopathogenetic hypothesis of these paradoxical effects are quite intriguing. The aim of this review is to collect and to analyze existing knowledge to better understand the pathogenetic mechanism of these complications and suggest new fields of investigation, improve therapeutic strategies of autoimmune diseases, and prevent and/or better address such complications.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058657083

Download citation: RISBibTeXText

PMID: 27663916


Related references

Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. Journal of the American Academy of Dermatology 60(5): 781-785, 2009

Anti-tumor necrosis factor-alpha-induced psoriasis. Journal of Rheumatology 33(7): 1411-1414, 2006

A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis. Arthritis and Rheumatism 43(3): 638-644, 2000

Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. Journal of the American Academy of Dermatology 67(6): 1349-1361, 2013

Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review. Infectious Diseases and Therapy 2(1): 59-73, 2013

Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Pediatric Dermatology 34(3): 253-260, 2017

The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study. Journal of the American Academy of Dermatology 66(5): E180-E182, 2012

Tumor necrosis factor-alpha inhibitors for the treatment of psoriasis patients with liver cirrhosis: A report of four cases with a literature review. Indian Journal of Dermatology, Venereology and Leprology 83(1): 55-59, 2016

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. American Journal of Clinical Dermatology 9(1): 1-14, 2007

Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatric Dermatology 29(4): 454-459, 2012

Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Seminars in Arthritis and Rheumatism 37(6): 381-387, 2007

Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review. Clinical Rheumatology 37(3): 849-853, 2018

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis and Rheumatism 58(5): 1248-1257, 2008

Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. Journal of the European Academy of Dermatology and Venereology 25(4): 471-474, 2011

Cat-scratch disease during anti-tumor necrosis factor-alpha therapy: case report and review of the literature. International Journal of Dermatology 53(3): E182-E183, 2014